Ert Pompe denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Deny ERT for Pompe Disease as Non-Formulary

Blue Cross Blue Shield formularies — the lists of covered drugs — are organized by tier, and most ERT products for rare diseases sit on specialty tiers that require prior authorization regardless of formulary status. A non-formulary denial means the specific ERT product prescribed is either not included on the plan's formulary at all, or it requires an exception to be covered. This situation arises when a plan covers one ERT product but not another, when a formulary changes mid-year, or when the prescriber selected a product not yet reviewed by the plan's pharmacy and therapeutics committee.

## Why This Denial Is Appealable

For rare diseases with narrow treatment options, formulary exception pathways exist precisely because the standard formulary may not include every FDA-approved option appropriate for a given patient. BCBS plans are required to have a formulary exception process, and medical necessity — combined with documentation that the non-formulary product is clinically superior or necessary for this specific patient — is the standard basis for an exception.

## Federal Appeal Framework

• Formulary exception request (first step): Before or alongside a formal appeal, submit a formulary exception request. This is typically a separate administrative pathway that allows the plan's pharmacy and therapeutics process to add coverage for a specific patient. The prescriber's medical necessity letter is central.
• Internal appeal: If the formulary exception is denied, you have the right to a formal internal appeal. File within the deadline on your denial letter. Request expedited review given the progressive nature of Pompe disease.
• External review (ACA §2719): After final internal denial, independent external review is available. The external-review window is typically four months from final denial.
• ERISA §503: Request the complete claims file, including the plan's formulary exception criteria, if employer-sponsored.

## Documentation to Gather

• Medical necessity letter for the non-formulary product: The treating physician must explain why this specific ERT product — rather than any formulary alternative — is medically necessary for this patient. Reasons may include: the formulary alternative is not clinically appropriate for the patient's specific presentation, the patient previously failed or had a clinical response issue with a formulary alternative, or no formulary alternative exists for this indication.
• Formulary alternative review: If BCBS's formulary includes an alternative ERT product, the prescriber should specifically address why that alternative is not appropriate (without fabricating contraindications — the physician documents actual clinical judgment from the chart).
• Diagnosis documentation: Genetic and/or enzymatic confirmation of Pompe disease to establish that the non-formulary product is being requested for an FDA-approved indication.
• FDA prescribing label: Confirm the non-formulary product has FDA approval for this indication.
• Prior treatment records (if applicable): If the patient has previously received treatment, document the clinical history and rationale for the current product selection.

## Criteria-Mapping Structure

Obtain the BCBS formulary exception criteria for specialty drugs. For each criterion:

| Exception Criterion | Supporting Documentation | |---|---| | Medical necessity of non-formulary product | [Prescriber letter explaining clinical rationale] | | FDA approval for the indication | [Prescribing label] | | Formulary alternative not appropriate (if applicable) | [Prescriber's clinical reasoning from chart] | | Confirmed Pompe disease diagnosis | [Diagnostic test results] |

Formulary exception and non-formulary appeals for rare-disease ERT products are strengthened significantly when the physician's letter addresses the formulary alternative directly, even if no alternative exists — in that case, the letter should state that no clinically equivalent formulary option is available for this indication.